10-K: Dynatronics Corporation 2024 Annual Report: Navigating Challenges and Focusing on Future Growth

Dynatronics Corporation's 2024 annual report reveals a decrease in net sales and a net loss, alongside strategic efforts to optimize operations and pursue acquisitions.

Summary

• Dynatronics Corporation experienced a decrease in net sales by $8.075 million, or 19.9%, reaching $32.534 million in fiscal year 2024, compared to $40.609 million in fiscal year 2023.
• The company's gross profit decreased by $2.515 million, or 24.8%, to $7.635 million, representing 23.5% of net sales, down from 25.0% in the previous year.
• Selling, general, and administrative expenses saw a significant reduction of $5.094 million, or 34.0%, totaling $9.908 million for fiscal year 2024.
• Interest expense increased by approximately $300,000, or 254.2%, to $418,000 due to a new line of credit.
• The company reported a pre-tax loss of $2.698 million for fiscal year 2024, compared to a loss of $4.973 million in the previous year.
• Net loss attributable to common stockholders was $3.429 million, or $1.00 per share, for fiscal year 2024, compared to a net loss of $5.664 million, or $1.46 per share, in fiscal year 2023.
• As of June 30, 2024, Dynatronics had $484,000 in cash and cash equivalents and a working capital of $2.853 million.
• The company's line of credit had an outstanding balance of $2.122 million as of June 30, 2024.
• Inventories decreased by $1.809 million, or 24.4%, to $5.594 million as of June 30, 2024.
• The company is focused on driving sales, increasing profitability, and pursuing merger and acquisition opportunities in fiscal year 2025.

Sentiment

Score: 4

Explanation: The document presents a mixed picture with significant challenges in revenue and profitability, but also highlights cost-cutting measures and strategic initiatives. The overall sentiment is cautiously negative due to the financial losses and market risks, but there are some positive aspects related to cost management and future plans.

Positives

• The company significantly reduced selling, general, and administrative expenses by 34.0%, indicating improved cost management.
• The pre-tax loss decreased from $4.973 million to $2.698 million, showing progress in financial performance.
• The company successfully reduced inventory levels by 24.4%, improving efficiency.
• Dynatronics secured a line of credit to provide additional operating capital.
• The company is actively pursuing an acquisition strategy to consolidate manufacturers in its core markets.

Negatives

• Net sales decreased by 19.9%, indicating a significant drop in revenue.
• Gross profit decreased by 24.8%, reflecting lower sales and reduced product margins.
• The company experienced a net loss of $3.429 million attributable to common stockholders.
• Working capital decreased from $4.478 million to $2.853 million, indicating a potential liquidity concern.
• Interest expense increased significantly due to the new line of credit.

Risks

• The company relies on third-party manufacturers, and any issues with their quality or effectiveness could harm the business.
• Disruptions in the supply chain, including those caused by geopolitical instability, could negatively impact operations.
• Inflation and price fluctuations of raw materials and energy could adversely affect profitability.
• The company faces risks related to health epidemics and other widespread outbreaks of contagious disease.
• The company has a history of losses and may not sustain profitability in the future.
• The company may need additional funding and may be unable to raise additional capital when needed.
• The company faces challenges in managing growth through acquisitions and integrating acquired businesses.
• Healthcare reform in the United States could have a significant effect on the company's business.
• The company's products are subject to extensive regulation by the FDA and other regulatory authorities.
• The company's commercial activities internationally are subject to special risks associated with corruption and trade sanctions.
• The company is subject to complex and evolving laws and regulations regarding privacy and data protection.
• The company faces intense competition from larger, well-established medical device companies.
• The company is dependent on its senior management team and other qualified personnel.
• Failures in the company's information technology systems could have a material adverse effect on the business.
• The company's stock price has been volatile and is expected to continue to be volatile.
• Investors in the company's securities may experience substantial dilution.
• The company's ability to issue preferred stock could delay or prevent takeover attempts.
• The company's common stock is now trading on the OTCQB Venture Market, which could cause trading to be more difficult.
• The company may pursue strategies that result in the deregistration of its common stock under the Exchange Act.

Future Outlook

The company is focused on driving sales through strategic partnerships, increasing operating profitability through disciplined product portfolio management, and pursuing merger and acquisition opportunities in its core markets in fiscal year 2025.

Management Comments

• The company is confident that the steps taken will position it for success moving forward.
• The company is focused on executing strategies to drive sales, increase profitability, and pursue acquisitions.
• Management believes that its cash generated from operations, current capital resources, and equity proceeds provide sufficient liquidity to fund operations for the next 12 months.

Industry Context

The company operates in a highly competitive market with numerous competitors of varying sizes, including personal care companies, branded consumer healthcare companies, and private label manufacturers. The industry is experiencing a consolidation trend, which could result in greater pricing pressures and limitations on the company's ability to sell to important market segments.

Comparison to Industry Standards

• The report does not provide specific comparisons to industry standards or competitors in terms of financial metrics.
• The company competes with large and well-capitalized companies such as Enovis and Ossur, which have more established relationships, broader product offerings, and greater resources.
• The company's reliance on third-party manufacturers is a common practice in the medical device industry, but it also introduces risks related to quality and supply chain disruptions.
• The company's focus on acquisitions is a common strategy for growth in the industry, but it also presents challenges related to integration and financial performance.
• The company's move to the OTCQB Venture Market is a significant change that could impact its trading volume and access to capital, which is a common issue for smaller companies.

Corporate Governance

Related Party Transactions

• The company leases facilities in New Jersey and Minnesota from employees, shareholders, and entities controlled by shareholders, who were previously principals of businesses acquired by the company.

Stakeholder Impact

• Shareholders may be concerned about the decrease in net sales, gross profit, and the net loss.
• Employees may be affected by cost-cutting measures and potential changes in the company's strategy.
• Customers may experience changes in product availability or pricing due to supply chain issues and cost fluctuations.
• Suppliers may be impacted by changes in the company's purchasing patterns and financial stability.
• Creditors may be concerned about the company's financial performance and ability to repay debts.

Next Steps

• The company will focus on driving sales through strategic partnerships.
• The company will increase operating profitability through disciplined product portfolio management.
• The company will pursue merger and acquisition opportunities in its core markets.
• The company will continue to evaluate and take action to preserve adequate liquidity.

Key Dates

Keywords

medical devices, restorative products, physical therapy, rehabilitation, orthopedics, pain management, athletic training, manufacturing, acquisitions, financial performance, supply chain, regulatory compliance, intellectual property, healthcare reform